Schizophrenia Research
Volume 115, Issue 2 , Pages 209-214 , December 2009

Reduced cerebrospinal fluid and plasma nerve growth factor in drug-naïve psychotic patients

  • Anvita Kale

      Affiliations

    • Interactive Research School for Health Affairs, Bharati Vidyapeeth, Pune 411043, India
    • ,
  • Sadhana Joshi

      Affiliations

    • Interactive Research School for Health Affairs, Bharati Vidyapeeth, Pune 411043, India
    • ,
  • Anilkumar Pillai

      Affiliations

    • Department of Psychiatry and Health Behavior, Medical College of Georgia, USA
    • Medical Research Service, Veterans Affairs Medical Center Augusta, GA, USA
    • ,
  • Nilesh Naphade

      Affiliations

    • Department of Psychiatry, Bharati Medical College, Bharati Vidyapeeth, Pune 411043, India
    • ,
  • MSVK Raju

      Affiliations

    • Department of Psychiatry, Bharati Medical College, Bharati Vidyapeeth, Pune 411043, India
    • ,
  • Henry Nasrallah

      Affiliations

    • Department of Psychiatry and Neurology, University of Cincinnati, Cincinnati, OH, USA
    • ,
  • Sahebarao P. Mahadik

      Affiliations

    • Department of Psychiatry and Health Behavior, Medical College of Georgia, USA
    • Medical Research Service, Veterans Affairs Medical Center Augusta, GA, USA
    • Corresponding Author InformationCorresponding author. Medical College of Georgia and Medical Research Service, Veterans Affairs Medical Center Augusta, GA, USA. Tel.: +1 706 733 0188; fax: +1 706 823 3949.

Received 3 February 2009 ,Revised 15 July 2009 ,Accepted 19 July 2009.

References 

  1. Akbarian S, Bunney WE, Potkin SG, Wigal SB, Hagman JO, Sandman CA, et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch. Gen. Psychiatry. 1993;50:169–177
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994;
  3. Angelucci F, Ricci V, Pomponi M, Conte G, Mathé AA, Tonali PA, et al. Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor. J. Psychopharmacol. 2007;21:820–825
  4. Arnold SE, Hyman BT, Van Hoesen GW, Damasio AR. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch. Gen. Psychiatry. 1991;48:625–632
  5. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr. Res. 2003;62:195–204
  6. Barde YA. Neurotrophins: a family of proteins supporting the survival of neurons. Prog. Clin. Biol. Res. 1994;390:45–56
  7. Benes FM, Sorensen I, Bird ED. Reduced neuronal size in posterior hippocampus of schizophrenic patients. Schizophr. Bull. 1991;17:597–608
  8. Berger GE, Wood SJ, Wellard RM, Proffitt TM, McConchie M, Amminger GP, et al. In vivo brain effects of ethyleicosapentaenoic acid in early psychosis. A 1H-MRS study. Neuropsychopharmacology. 2008;33:2467–2473
  9. Bersani G, Iannitelli A, Maselli P, Pancheri P, Aloe L, Angelucci F, et al. Low nerve growth factor plasma levels in schizophrenic patients: a preliminary study. Schizophr. Res. 1999;37:201–203
  10. Bersani G, Iannitelli A, Massoni E, Garavini A, Grilli A, Di Giannantonio M, et al. Ultradian variation of nerve growth factor plasma levels in healthy and schizophrenic subjects. Int. J. Immunopathol. Pharmacol. 2004;17:367–372
  11. Bilder RM, Reiter G, Bates J, Lencz T, Szeszko P, Goldman RS, et al. Cognitive development in schizophrenia: follow-back from the first episode. J. Clin. Exp. Neuropsychol. 2006;28:270–282
  12. Birling MC, Price J. Influence of growth factors on neuronal differentiation. Curr. Opinion Cell Biol. 1995;7:878–884
  13. Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S. Brain derived neurotropic factor in first-episode psychosis. Schizophr. Res. 2007;91:1–5
  14. Buckley PF, Mahadik S, Pillai A, Terry A. Neurotrophins and schizophrenia. Schizophr. Res. 2007;94:1–11
  15. Cannon M, Dean K, Jones PB. Early environmental risk factors for schizophrenia. In:  Keshavan M,  Kennedy J,  Murray R editor. Neurodevelopment and Schizophrenia. Cambridge University Press; 2004;p. 191–209
  16. Durany N, Michel T, Zöchling R, Boissl KW, Cruz-Sánchez FF, Riederer P, et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 2001;52:79–86
  17. Gnahn H, Hefti F, Heumann R, Schwab ME, Thoenen H. NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: evidence for a physiological role of NGF in the brain?. Brain Res. 1983;285:45–52
  18. Goedert M, Fine A, Hunt SP, Ullrich A. Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: lesion effects in the rat brain and levels in Alzheimer's disease. Brain Res. 1986;387:85–92
  19. Hefti F, Hartikka J, Salvatierra A, Weiner WJ, Mash DC. Localization of nerve growth factor receptors in cholinergic neurons of the human basal forebrain. Neurosci. Lett. 1986;69:37–41
  20. Holt DJ, Herman MM, Hyde TM, Kleinman JE, Sinton CM, German DC, et al. Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience. 1999;94:21–31
  21. Horton AR, Davies AM, Buj-Bello A, Bartlett P, Murphy M. Leukemia inhibitory factor and ciliary neurotrophic factor in sensory neuron development. Perspect. Dev. Neurobiol. 1996;4:35–38
  22. Ikemoto A, Nitta A, Furukawa S, Ohishi M, Nakamura A, Fujii Y, et al. Dietary n−3 fatty acid deficiency decreases nerve growth factor content in rat hippocampus. Neurosci. Lett. 2000;285:99–102
  23. Jakob H, Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J. Neural. Transm. 1986;65:303–326
  24. Jockers-Scherübl MC, Bauer A, Kuhn S, Reischies F, Danker-Hopfe H, Schmidt LG, et al. Nerve growth factor in serum is a marker of the stage of alcohol disease. Neurosci. Lett. 2007;419:78–82
  25. Kale A, Joshi S, Naphade N, Sapkale S, Raju MSVK, Pillai A, et al. Opposite changes in predominantly docosahexaenoic acid (DHA) in cerebrospinal fluid and red blood cells from never-medicated first-episode psychotic patients. Schizophr. Res. 2008;98:295–301
  26. Kale, A., Naphade, N., Sapkale, S., Raju, M.S.V.K., Pillai, A., Joshi, S., Mahadik, S., in press. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: Implications for altered one-carbon metabolism. Psychiatry Res.
  27. Keshavan M, Montrose DM, Rajarethinam R, Diwadkar V, Prasad K, Sweeney JA. Psychopathology among offspring of parents with schizophrenia: relationship to premorbid impairments. Schizophr. Res. 2008;103:114–120
  28. Lauer M, Beckmann H, Senitz D. Increased frequency of dentate granule cells with basal dendrites in the hippocampal formation of schizophrenics. Psychiatry Res. 2003;22:89–97
  29. Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Ann. Rev. Neurosci. 2002;25:409–432
  30. Lindholm D, Hamnér S, Zirrgiebel U. Neurotrophins and cerebellar development. Perspect. Dev. Neurobiol. 1997;5:83–94
  31. Mahadik SP, Yao JK. Phospholipids in schizophrenia. In:  Lieberman JA,  Stroup TS,  Perkins DO editor. Textbook of Schizophrenia. Washington, DC: American Psychiatric Publishing; 2006;p. 117–135
  32. Mahadik SP, Pillai A, Joshi S, Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int. Rev. Psychiatry. 2006;18:119–131
  33. Mathalon DM, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes of the clinical course of schizophrenia in men. Arch. Gen. Psychiatry. 2001;58:148–157
  34. McNamara RR, Carlson SE. Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. Prostagland. Leukot. Essent Fatty Acids. 2006;75:329–349
  35. McNamara RK, Jandacek R, Rider T, Tso P, Hahn CG, Richtand NM, et al. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophr. Res. 2007;91:37–50
  36. Nawa H, Futamura T, Mizuno M, Takahashi M, Toyooka K, Someya T. Contribution of neurotrophic factors and cytokines to schizophrenia. Nippon Rinsho. 2003;61:521–528
  37. Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr. Res. 2003;60:117–123
  38. Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. In association with the E-E Multicenter Study Group. J. Psychiatr. Res. 2002;vol. 36:7–18
  39. Petronis A. Schizophrenia, neurodevelopment and epigenesis. In:  Keshavan M,  Kennedy J,  Murray R editor. Neurodevelopment and Schizophrenia. Cambridge University Press; 2004;p. 174–190
  40. Pillai A. Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals. 2008;16:183–193
  41. Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP, et al. Postmortem studies in schizophrenia. Schizophr. Bull. 1998;24:325–341
  42. Rao JS, Ertley RN, Lee HJ, DeMar JC, Arnold JT, Rapoport SI, et al. n−3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol. Psychiatry. 2007;12:36–46
  43. Riikonen R, Vanhala R. Levels of cerebrospinal fluid nerve-growth factor differ in infantile autism and Rett syndrome. Dev. Med. Child. Neurol. 1999;41:148–152
  44. Rund BR, Melle I, Friis S, Johannessen JO, Larsen TK, Midbøe LJ, et al. The course of neurocognitive functioning in first-episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse. Schizophr. Res. 2007;91:132–140
  45. Schlotz, W., Phillips, D.I., in press. Fetal origins of mental health: evidence and mechanisms. Brain Behav Immun. doi:10.1016/j.bbi.2009.02.001.
  46. Shimode H, Ueki A, Morita Y. Nerve growth factor attenuates hippocampal cholinergic deficits and operant learning impairment in rats with entorhinal cortex lesions. Behav. Pharmacol. 2003;14:179–190
  47. Shoval G, Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur. Neuropsychopharmacol. 2005;15:319–329
  48. Snider WD, Johnson EM. Neurotrophic molecules. Ann. Neurol. 1989;26:489–506
  49. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K, et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol. Psychiatry. 2000;5:293–300
  50. Talamini LM, Koch T, Luiten PG, Koolhaas JM, Korf J. Interruptions of early cortical development affect limbic association areas and social behaviour in rats; possible relevance for neurodevelopmental disorders. Brain Res. 1999;13:105–120
  51. Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch. Gen. Psychiatry. 1989;46:745–753
  52. Thoenen H. Neurotrophins and neuronal plasticity. Science. 1995;270:593–598
  53. Thoenen H, Edgar D. Neurotrophic factors. Science. 1985;229:238–242
  54. Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, Knable MB. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol. Psychiatry. 2005;57:252–260
  55. Voss B, Thienel R, Leucht S, Kircher T. Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview. Nervenarzt. 2008;79:47–4850–52, 54–59
  56. Wechsler, D., 2008. Wechsler Adult Intelligence Scale-Revised. The Psychological Corporation, San Antonio.
  57. Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J. Neurotrauma. 2004;21:1457–1467
  58. Yamazawa R, Nemoto T, Kobayashi H, Chino B, Kashima H, Mizuno M. Association between duration of untreated psychosis, premorbid functioning, and cognitive performance and the outcome of first-episode schizophrenia in Japanese patients: prospective study. Aust. N. Z. J. Psychiatry. 2008;42:159–165
  59. Zettler C, Bridges DC, Zhou XF, Rush RA. Detection of increased tissue concentrations of nerve growth factor with an improved extraction procedure. J. Neurosci. Res. 1996;46:581–594

PII: S0920-9964(09)00337-5

doi: 10.1016/j.schres.2009.07.022

Schizophrenia Research
Volume 115, Issue 2 , Pages 209-214 , December 2009

Article Tools

* Image Usage & Resolution